

DYNAVAX TECHNOLOGIES CORP  
Form 8-K  
May 26, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**Current Report**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 5/24/2010

**Dynavax Technologies Corporation**

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware  
(State or other jurisdiction

of incorporation)

33-0728374  
(IRS Employer

Identification No.)

Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 8-K

**2929 Seventh Street, Suite 100**

**Berkeley, CA 94710-2753**

(Address of principal executive offices, including zip code)

**(510) 848-5100**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 5.02. Departure of Directors or Certain Officers; Elections of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

***(b) Resignation of Director***

David M. Lawrence, M.D. resigned from the board of directors, including serving as a member of the Compensation Committee, of Dynavax Technologies Corporation ( Dynavax or the Company ) due to other commitments, effective May 31, 2010. There were no disagreements between Dr. Lawrence and the Company on any matter relating to Dynavax 's operations, policies or practices.

**Signature(s)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DYNAVAX TECHNOLOGIES CORPORATION**

Date: May 26, 2010

By: */s/* **MICHAEL S. OSTRACH**  
**Michael S. Ostrach**

**Vice President**